Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.7%

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) traded down 4.7% during trading on Friday . The stock traded as low as $30.11 and last traded at $30.13. 303,617 shares changed hands during trading, a decline of 53% from the average session volume of 640,214 shares. The stock had previously closed at $31.63.

Analyst Ratings Changes

Several analysts have recently commented on the stock. JMP Securities decreased their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a research report on Wednesday, April 3rd. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Finally, Truist Financial decreased their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Stock Performance

The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The business’s 50 day moving average is $36.85 and its 200 day moving average is $39.08. The stock has a market capitalization of $2.25 billion, a PE ratio of 34.55, a PEG ratio of 0.95 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period last year, the firm earned $0.94 earnings per share. Integra LifeSciences’s quarterly revenue was down .3% on a year-over-year basis. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently modified their holdings of the business. Signaturefd LLC raised its stake in shares of Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after acquiring an additional 415 shares in the last quarter. Hexagon Capital Partners LLC boosted its holdings in Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after buying an additional 370 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Integra LifeSciences by 469.5% during the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after buying an additional 615 shares in the last quarter. Gladius Capital Management LP acquired a new position in Integra LifeSciences during the third quarter worth $47,000. Finally, Valley National Advisers Inc. acquired a new position in Integra LifeSciences during the first quarter worth $63,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.